Anticoagulant therapy for patients with ischaemic stroke

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) James V. Freeman et al.   ANNALS OF INTERNAL MEDICINE

Dabigatran Association With Higher Risk of Acute Coronary Events

(2012) Ken Uchino   ARCHIVES OF INTERNAL MEDICINE

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

(2012) Stefan H. Hohnloser et al.   CIRCULATION

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

(2012) Graeme J Hankey et al.   LANCET NEUROLOGY

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial

(2012) Hans-Christoph Diener et al.   LANCET NEUROLOGY

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

(2011) John A. Cairns et al.   CANADIAN JOURNAL OF CARDIOLOGY

Fibrinolytic Treatment of Acute Ischemic Stroke for Patients on New Oral Anticoagulant Drugs

(2011) Carl-Erik Dempfle et al.   CEREBROVASCULAR DISEASES

Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation

(2011) Shimoli V. Shah et al.   CIRCULATION

Dabigatran Etexilate

(2011) Graeme J. Hankey et al.   CIRCULATION

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)

(2011) L. Samuel Wann et al.   CIRCULATION

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

(2011) Elise S. Eerenberg et al.   CIRCULATION

Laboratory assessment of new anticoagulants

(2011) Meyer M. Samama et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran

(2011) B. Nhi Beasley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-Molecular-Weight Heparin Versus Aspirin for Acute Ischemic Stroke With Large Artery Occlusive Disease

(2011) Qiao Shu Wang et al.   STROKE

Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?

(2011) Armando Tripodi   THROMBOSIS AND HAEMOSTASIS

Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation

(2011) Charles Esmon et al.   THROMBOSIS AND HAEMOSTASIS

Bleeding risk assessment and management in atrial fibrillation patients

(2011) Laurent Fauchier et al.   THROMBOSIS AND HAEMOSTASIS

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study

(2011) Gregory Lip et al.   THROMBOSIS AND HAEMOSTASIS

Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement

(2011) Geneviève Freyburger et al.   THROMBOSIS RESEARCH

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

(2010) Christian T. Ruff et al.   AMERICAN HEART JOURNAL

Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

(2010) Isla M. Ogilvie et al.   AMERICAN JOURNAL OF MEDICINE

Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism

(2010) Bengt I. Eriksson et al.   Annual Review of Medicine

Moving the Tipping Point

(2010) Mark H. Eckman et al.  

Adherence to Medicines in the Older-Aged with Chronic Conditions

(2010) Sheila A. Doggrell   DRUGS & AGING

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPACE

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study

(2010) A. TRIPODI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

(2010) Hans-Christoph Diener et al.   LANCET NEUROLOGY

Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

(2010) Marcel Levi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

(2010) Edelgard Lindhoff-Last et al.   THERAPEUTIC DRUG MONITORING

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

(2010) Jean Amiral et al.   THROMBOSIS AND HAEMOSTASIS

Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate

(2010) Gregory Y. H. Lip et al.   THROMBOSIS AND HAEMOSTASIS

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

(2010) Jean-Luc Martinoli et al.   THROMBOSIS AND HAEMOSTASIS

The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?

(2010) John W. Eikelboom et al.   THROMBOSIS AND HAEMOSTASIS

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy

(2010) Gregory Y.H. Lip et al.   THROMBOSIS RESEARCH

The Role of Tissue Factor and Factor VIIa in Hemostasis

(2009) Nigel Mackman   ANESTHESIA AND ANALGESIA

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST

Medication Adherence

(2009) P. Michael Ho et al.   CIRCULATION

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

(2009) C. Weinz et al.   DRUG METABOLISM AND DISPOSITION

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

(2009) G. Y.H. Lip et al.   EUROPEAN HEART JOURNAL

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation

(2008) Yi Wan et al.  

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

(2008) Dagmar Kubitza et al.   CURRENT MEDICAL RESEARCH AND OPINION

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

(2008) Jennifer Carreiro et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

What do the results of the PRoFESS trial teach us?

(2008) Graeme J Hankey et al.   LANCET NEUROLOGY

Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk

(2008) Jeff S. Healey et al.   STROKE